Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b

by Kristina Levan, Matin Mehryar, Constantina Mateoiu, Per Albertsson, Tom Bäck, Karin Sundfeldt
Published 2017-05-01

Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer

by Stig Palm, Tom Bäck, Emma Aneheim, Andreas Hallqvist, Ragnar Hultborn, Lars Jacobsson, Holger Jensen, Sture Lindegren, Per Albertsson
Published 2021-01-01

Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model

by Jessie R. Nedrow, Anders Josefsson, Sunju Park, Tom Bäck, Robert F. Hobbs, Cory Brayton, Frank Bruchertseifer, Alfred Morgenstern, George Sgouros
Published 2017-07-01

Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model

by Anna Gustafsson-Lutz, Tom Bäck, Emma Aneheim, Ragnar Hultborn, Stig Palm, Lars Jacobsson, Alfred Morgenstern, Frank Bruchertseifer, Per Albertsson, Sture Lindegren
Published 2017-04-01

Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.

by Sture Lindegren, Luciana N S Andrade, Tom Bäck, Camila Maria L Machado, Bruno Brasil Horta, Carlos Buchpiguel, Ana Maria Moro, Oswaldo Keith Okamoto, Lars Jacobsson, Elin Cederkrantz, Kohshin Washiyama, Emma Aneheim, Stig Palm, Holger Jensen, Maria Carolina B Tuma, Roger Chammas, Ragnar Hultborn, Per Albertsson
Published 2015-01-01